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Abstract
B cells are recognized as main actors in the autoimmune process. Autoreactive B cells can arise in the
bone marrow or in the periphery and, if not properly inhibited or eliminated, can lead to autoimmune
diseases through several mechanisms: autoantibody production and immune complex formation,
cytokine and chemokine synthesis, antigen presentation, T cell activation, and ectopic lymphogenesis.
The availability of agents capable of depleting B cells (that is, anti-CD20 and anti-CD22 monoclonal
antibodies) or targeting B cell survival factors (atacicept and belimumab) opens new perspectives in




used is definitely rituximab. Rituximab is a glycosylated
immunoglobulin G (IgG) chimeric mouse/human anti-
body that binds to the CD20 antigen present on the
majority of circulating B cells [1]. Expression of CD20 is
restricted to the B cell lineage from the pre-B-cell stage
until terminal differentiation into plasma cells. Treatment
withrituximabinducesanotablyrapid(withinhours)and
prolonged (more than 3 months) depletion of circulating
B cells. Interestingly, naïve B cells appear to recover faster
than memory B cells. The manner and speed of action of
rituximab could potentially suggest an effect related to
antibody-independent B cell function, whereas an anti-
body-mediated effect would not have been so fast since
plasma cells are CD20-negative and thus not directly
affected by rituximab [2]. Although this has been nicely
demonstrated in autoimmune diseases, in the case of
immune-mediated thrombocytopenia, Bussel [3] has
defined three different phenotypic responses with very
different kinetics of clinical response. In diseases such as
pemphigus vulgaris, it has been clearly demonstrated that
the mechanism of rituximab action is through eradication
of the anti-keratinocyte IgG4 autoantibody [4]. However,
many issues, such as the persistence of memory B cells or
the ability of this drug to induce an in-depth depletion,
remained to be defined.
Major recent advances
B cells and rheumatoid arthritis
Significant evidence arising from experimental models
indicates that autoantibodies play a key role in the
pathogenesis of inflammatory arthritis; moreover, B cell
depletion therapy with rituximab provides evidence that
B cells play a major role in rheumatoid arthritis (RA) [5].
In addition to autoantibody production, B cells effi-
ciently present antigen to T cells. Rheumatoid factor
(RF)-producing B cells are particularly effective in
presenting immune complexes to T cells [6]; they
produce soluble factors, including cytokines and che-
mokines, that can modulate dendritic cell migration and
function [7] and form tertiary or ectopic lymphoid tissue,
which ranges from loose aggregates of T and B cells to
distinct follicle-like structures in close contact with the
synovial membrane of RA patients, amplifying auto-
immune responses and inflammation [8].
B cells and systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by formation of pathogenic
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damage and failure [9]. A central role for B cells is evident
and is confirmed by the therapeutic potential of B cell
depleting treatment in humans [10,11]. Autoantibody
production contributes to SLE development by inducing
immune complex-mediated type III hypersensitivity and
type II antibody-dependent cytotoxicity. Moreover, anti-
body deposition can instruct innate immune cells to
produce pathogenic cytokines such as interferon-alpha
(IFNa), tumor necrosis factor (TNF), and interleukin-1
(IL-1) [12]. Several abnormalities of B cells have been
related to an SLE-like phenotype; Bolland and colleagues
[13] demonstrated how some of the genes involved in
lupus may downregulate B cell receptor signaling at the
immature stage, impairing B cell tolerance. Alterations in
B cell longevity can also cause an SLE-like phonotype;
transgenic expression of BAFF (B cell activator of the TNF
family), a cytokine promoting B cell survival, leads to a
lupus-like phenotype with high mature B cell and
plasma cell numbers, spontaneous germinal center
reactions, autoantibodies, and Ig deposition in the
kidney [14]. Moreover, administration of soluble BAFF
receptor ameliorates disease progression and survival; in
human serum, elevated BAFF correlates with serum IgG
and autoantibody levels [15] and excessive BAFF
promotes the survival of autoreactive B cells in the
periphery [16]. The breakdown of B cell tolerance occurs
at a very early stage of development in both mice and
humans [17] and may precede or trigger other immune
abnormalities, as shown by the expression of antinuclear
antibodies in SLE patients several years before the onset
of clinical disease [18].
B cells and type 1 diabetes
Type 1 diabetes (T1D) is an autoimmune disease
characterized by T-cell mediated destruction of insulin-
producing pancreatic b cells [19]. T1D involves the
interaction of different subsets of lymphocytes and
antigen-presenting cells; in particular, B lymphocytes,
because of their highly efficient ability to internalize
b cell antigens through Ig and subsequently present them
to autoreactive CD4 T-cells, they serve as a preferential
subset of diabetogenic antigen-presenting cells in non-
obese diabetic (NOD) mice and possibly in humans
[20]. Indeed, B cell-deficient NOD mice have been
shown to be protected from autoimmune diabetes [21]
and to be deficient in the development of the major
autoantigen T-cell response (such as glutamate decar-
boxylase) [22]. These findings have made B cell targeting
a new and attractive strategy for the treatment of T1D.
Work by Hu and colleagues [23] showed the positive
effects of an anti-CD20-based B cell depleting strategy,
preventing autoimmune diabetes and reversing estab-
lished diabetes, in transgenic NOD mice expressing the
humanized CD20 receptor on B cells. The actual use of
B cell depletion as a therapy for human autoimmune
disease, including its use in patients with new-onset T1D,
is ongoing [24]. Recent work by our group suggested a
novel approach: a newly developed reagent, anti-CD22
calicheamicin-conjugated monoclonal antibody (mAb)
[25], which has been previously tested in humans, both
for the immunoregulatory properties of CD22 engage-
ment and for the possibility of depleting mature B cells.
It has had promising results in the fields of autoimmune
disease [26] and B cell malignancies [27], but had not
been tested in diabetes until recently. The study shows
how anti-CD22 calicheamicin-conjugated mAb treat-
ment can delay diabetes onset in prediabetic NOD mice
and, more importantly, can restore normoglycemia in
new-onset hyperglycemic NOD mice. Moreover, for the
very first time, data highlight that re-emerging B cells in
NOD mice display a different phenotype from naïve
B cells; they are functionally impaired in their ability to
present antigen and can regulate the autoimmune
response, resulting in long-term tolerance to autoanti-
gens in vivo [25].
B cells and multiple sclerosis
In addition to T cell responses, B cell and antibody
responses may contribute to the pathogenesis of multiple
sclerosis (MS) [28]. Antimyelin autoantibodies such as
those directed against myelin basic protein and myelin
oligodendrocyte glycoprotein can target damage in both
animal and human inflammatory central nervous system
diseases [29]. B cells are also able to internalize and
present antigens through the B cellreceptoratleast10,000
times more efficiently than professional antigen-present-
ing cells, and can activate T cells, produce cytokines such
as IL-6 and IL-10 that affect the local environment, play a
role in the formation and maintenance of lymphoid-like
follicles in the ventricular-meningeal compartment [30],
and harbor the Epstein-Barr virus in a chronically
activated state.
Future directions
New approaches to targeting the B cell compartment are
under investigation. Trials with anti-CD20 mAbs have
been published recently in MS [2], RA [5], and SLE
[10,11] and should be published soon for T1D. Whereas
anti-CD20 therapy for MS and RA has been successful,
many limitations appear to be evident when it is used
for SLE and T1D, possibly due to the presence of highly
specialized memory B cells resistant to depletion, or to
the potential inability of anti-CD20 to deplete B cells in
the pancreas or in tertiary lymphoid tissue.
None of the published trials for SLE are controlled, and
work presented at the 2008 American College of
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from a placebo-controlled trial on the use of rituximab in
nonrenal SLE (EXPLORER). Thus, another negative trial
of rituximab in lupus nephritis (LUNAR) would suggest
that anti-CD20 mAb might be inefficacious in human
SLE.
Therefore, there is a need for new agents targeting
memory B cells/plasma cells and agents selective for
autoreactive B cells. Selective modulation of B cells has
been achieved recently with a humanized mAb against
the B cell surface marker CD22. This antibody (epratu-
zumab) has been reported to be effective, with the same
safety profile, in two prototype autoimmune diseases,
SLE and primary Sjögren syndrome [31,32]. Other drugs,
such as atacicept (a fully human recombinant fusion
protein that blocks the activity of B-lymphocyte stimu-
lator [BLyS] and of a proliferation-inducing ligand
[APRIL]) and belimumab (LymphoStat-B®, a human
mAb that specifically recognizes and inhibits the
biological activity of BLyS), inhibit specific B cell survival
factors, resulting in reductions in B cells and plasma cells
[33]. These drugs are undergoing clinical evaluation in
phase II and III studies in patients with relapsing MS,
SLE, lupus nephritis, RA, and several B cell malignancies.
The use of these drugs induces a reversible decrease in
circulating Ig concentration and a reduction in mature B
cells in the peripheral blood and lymphoid tissues [34].
Unfortunately, the lupus nephritis trial involving ataci-
cept was stopped earlier this year due to increased
frequency of severe infections. The other studies of
atacicept in SLE, RA, and MS are proceeding. For the sake
of completeness, we would like to mention the devel-
opment of anti-CD19 mAbs, as well as the single-chain
CD20-binding polypeptides that are being co-developed
by Trubion Pharmaceuticals Inc (Seattle, WA, USA) and
Wyeth (Madison, NJ, USA). Finally, a lupus trial using
abetimus (a double-stranded oligodeoxyribonucleotide
thylene glycol that was developed to induce tolerance in
B cells directed against double-stranded DNA) was
recently stopped because of an interim analysis showing
futility.
Two recent papers show a new regulatory role for specific
subsets of B cells in MS and T1D, confirming that B cells
can abrogate T cell immune response when co-adop-
tively transfered with autoreactive T cells or can halt
disease progression [25,35].
The paper from Tedder and colleagues [35] showed that
B cells play critical positive and negative regulatory roles
in a murine model of MS [experimental autoimmune
encephalomyelitis (EAE)]. B cell depletion had two
opposing effects on disease [35]. Early B cell depletion
exacerbated not only EAE induction, but also the
recovery phase of disease [35]. Moreover, the adoptive
transfer of IL-10-producing regulatory B10 cells, but not
other B cells, normalized EAE pathogenesis [35]. There-
fore, investigators proposed that increased EAE severity
following total B cell depletion before disease induction
results from depletion of the B10-cell subset [35].
Regulatory B cells may be critical during disease
induction and for resolving disease. In contrast, B cell
depletion after the onset of EAE symptoms ameliorated
disease progression [35], making this strategy applicable
for treating human MS after disease onset.
Anti-CD20 mAb treatment depletes memory cells in
mice but does not deplete long-lived plasma cells [32].
Thus, CD20
+ B-cell depletion may be most beneficial
when carried out before the long-lived plasma cell pool
is established.
Therefore, future studies will investigate selectivity and
specific depletion/targeting of autoreactive B cells and
expansion of regulatory B cells.
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